A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3, Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
Sponsor: MoonLake Immunotherapeutics AG
This PHASE3 trial investigates Hidradenitis Suppurativa and is currently ongoing. MoonLake Immunotherapeutics AG leads this study, which shows 4 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
Mar 2026 — Present [monthly]
Enrolling By Invitation PHASE3
-
Oct 2025 — Mar 2026 [monthly]
Enrolling By Invitation PHASE3
-
Aug 2025 — Oct 2025 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jun 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MoonLake Immunotherapeutics AG
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aventura, United States , Badalona, Spain , Barcelona, Spain , Barrie, Canada , Berlin, Germany , Birmingham, United States , Boardman, United States , Bochum, Germany , Boston, United States , Bramsche, Germany and 68 more locations